This week in cardiology from heartwire
View all posts »#86: Calcium supplements and CV risk; FDA on olmesartan benefits; low LDLs in JUPITER; AHA statement on triglycerides; refuting alleged ARB-cancer link
Apr 21, 2011 10:50 EDT-
1Comments
-
Read later
For the week ending April 21, 2011 we discuss the following top cardiology news from heartwire:
- Calcium supplements and cardiovascular events: New data, more debate
- Olmesartan benefits outweigh potential CV harms, says FDA
- JUPITER: Best CVD event reduction in patients with very low LDL-cholesterol levels
- Diet and exercise key for treating high triglycerides: New AHA statement
- No cancer risk elevation from ARBs: Two new analyses
And also, in brief:
- Ambitious predictions as Yusuf preaches prevention
- Cell therapy improves function in severe HF patients
- Wake-up call: Quality and quantity of sleep are important for CVD risk
Join us for a comprehensive review of this week's most important cardiology news.
Your comments
 |
 |
 |
||
 |
|
 |
||
 |
 |
 |
||
 |
|
|
 |
|
 |
 |
 |
||
 |
|
|
 |
|
|
|
|
||
|
||||
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
